The impact of GLP-1 RAs on alcohol use is explored, showing potential benefits in reducing intake and cravings, but with ...

A groundbreaking Harvard study reveals that semaglutide could benefit more people in the U.S. than ever imagined.

Treatment with metformin was associated with a reduction in asthma attacks among patients with asthma and type 2 diabetes, with additional reductions observed with the use of GLP-1 receptor agonists, ...

Driving business growth through innovative food and nutrition strategies for CPG & foodservice brands. 💡 The Rise of GLP-1 ...

Study estimates 136.8 million U.S. adults are eligible for semaglutide, a popular therapy for diabetes, weight loss, and cardiovascular disease.

TUESDAY, Nov. 19, 2024 (HealthDay News) -- More than half of all American adults, almost 137 million people, could be ...

“The results of this cohort study suggest that metformin was associated with a lower rate of asthma attacks, with further reductions with the use of GLP-1 RA,” the authors write. “This appeared to be ...

Coya Therapeutics (COYA) releases the following letter to stockholders from Chief Executive Officer Dr. Arun Swaminathan….”Given my recent ...

Tennessee's Medicaid program, TennCare, covers drugs like Ozempic and Mounjaro to treat those with diabetes and heart ...

The holidays are near, and so is the season of eating decadent meals – and sometimes, overeating. Overindulging on food is ...

As GLP-1 drugs like Ozempic soar in popularity for weight loss, this film follows three people on their own GLP-1 journeys and explores how decades of diet culture and society’s relentless pursuit of ...

Three-fourths of U.S. adults are now overweight or have obesity, with nearly 260 million predicted to have overweight or ...